Novan — Corporate Update (September 2021)
35 slides from Novan's corporate update, Sep 9, 2021
Slide 1: Nitric Oxide-Based Medicine Corporate Update
Nitric Oxide-Based Medicine N A S D A Q : N O V N | n o v a n . c o m C O R P O R AT E U P D AT E / S E P T E M B E R 9 , 2 0 2 1 Exhibit 99.2
Slide 2: Forward-Looking Statements
NOVAN.COM FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements including, but not limited to, statements related to the potential therapeutic value of the Company’s NITRICIL™ platform technology, the Company’s pharmaceutical development of nitric oxide-releasing product c
Slide 3: A world leader in nitric oxide-based science, technology, and clinical translation
A world leader in nitric oxide-based science, technology, and clinical translation in support of delivering safe and efficacious therapies
Slide 4: Agenda
NOVAN.COM AGENDA 4 A Compelling Investment Opportunity Our History of R&D and Innovation Our Near-Term Strategy Our Commercialization Plan Our Full Opportunity Why Novan – Why Now
Slide 5: A Compelling Investment Opportunity
NOVAN.COM A COMPELLING INVESTMENT OPPORTUNITY Clinically proven platform technology, NITRICIL™ Robust body of data with nearly 4,000 treated subjects supporting anti-microbial and anti-inflammatory properties Positive topline results from pivotal Phase 3 study of SB206 in patients with molluscum con
Slide 6: Three NDAs Planned Over Three Years
NOVAN.COM THREE NDAs PLANNED OVER THREE YEARS 6 Product Candidate Indication Pre-IND Phase 1 Phase 2 Phase 3 Approval NDA Submission Targeted Novan Revenue Retention2 DERMATOLOGY SB206 Molluscum Q3 2022 ~85% N. America3 >95% ROW (ex. Japan4) SB204 Acne Vulgaris 20241 ~95% N. America >95% ROW (ex. Ja
Slide 7: Potential Value Creation
NOVAN.COM Potential Value Creation 7 Product Candidate SB206 SB204 SB019 Type Topical Gel Topical Gel Nasal Suspension Indication Molluscum Acne COVID-19 Potential Global Addressable Market ~12 Million1 ~733 Million2 ~134 Million3 Current Treatment Options In-office procedures; off label scripts Ant
Slide 8: NITRICIL
NOVAN.COM NITRICIL™ 8 Clinically proven proprietary nitric oxide (NO)-based technology platform Macromolecular New Chemical Entities (NCEs) Storage: ability to store therapeutic quantities of NO Tunability: pH-controlled NO release profiles Targeted: delivery of NO to site of infection or inflammati
Slide 9: Value Drivers Beyond 2024
NOVAN.COM VALUE DRIVERS BEYOND 2024 9 Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 DERMATOLOGY SB414 Atopic Dermatitis Psoriasis SB208 Tinea Pedis MEN’S AND WOMEN’S HEALTH SB207 Genital Warts WH504 High-Risk HPV WH602 High-Risk HPV COMPANION ANIMAL NVN4100 Various Ongoing Ongoing
Slide 10: Strategy Towards Driving Near-Term Stakeholder Value
STRATEGY TOWARDS DRIVING NEAR-TERM STAKEHOLDER VALUE Leverage core synergies of science, capital, resources and patient needs to create value by bringing new nitric oxide-based medicines to market
Slide 11: SB206 Molluscum Contagiosum
NOVAN.COM SB206 Molluscum Contagiosum 11 Positive topline results from pivotal Phase 3 with NDA submission targeted Q3 2022
Slide 12: Molluscum Market Potential for SB206
NOVAN.COM MOLLUSCUM MARKET POTENTIAL FOR SB206 Contagious skin infection caused by the molluscipoxvirus, a double-stranded DNA virus 12 High unmet medical need for topical at-home solution Prevalence rate in children 0-16 years old is 5.1% - 11.5% in the U.S.1 U.S. addressable market of ~6 million2
Slide 13: Pivotal Phase 3: Primary Efficacy Endpoint
NOVAN.COM PIVOTAL PHASE 3: PRIMARY EFFICACY ENDPOINT 13 Complete Clearance of Lesions 0.9% 3.6% 11.6% 19.7% 1.4% 7.2% 19.6% 32.4% 0.0% 5.0% 10.0% 15.0% 20.0% 25.0% 30.0% 35.0% Week 2 Week 4 Week 8 Week 12 Vehicle SB206 p-value <0.05 p-value <0.01 p-value <0.001 p-value <0.0001 * ** *** **** **** **
Slide 14: Pivotal Phase 3: Secondary Endpoints
NOVAN.COM PIVOTAL PHASE 3: SECONDARY ENDPOINTS 14 90% Clearance and 0 or 1 Remaining Lesions at Week 12 0.00% 5.00% 10.00% 15.00% 20.00% 25.00% 30.00% 35.00% 40.00% 45.00% 50.00% 90% Clearance at Week 12 0 or 1 Lesions at Week 12 Vehicle SB206 ******** p-value <0.0001****
Slide 15: Pivotal Phase 3: Secondary Endpoint - Change at Week 12
NOVAN.COM PIVOTAL PHASE 3: SECONDARY ENDPOINT - CHANGE AT WEEK 4 15 -60% -50% -40% -30% -20% -10% 0% BL Week 2 Week 4 Week 8 Week 12 Vehicle SB206 p-value <0.05 p-value <0.01 p-value <0.001 p-value <0.0001 * ** *** **** **** **** **** *** % Change From Baseline Lesion Count
Slide 16: Path Towards Potential Approval
NOVAN.COM PATH TOWARDS POTENTIAL APPROVAL 16 SB206 Targets to be the First FDA-Approved, In-Home Topical Treatment for Molluscum Finalize B-SIMPLE4 Week-24 Readout 3Q 2021 1H 2022 3Q 2022 Launch Pre-Commercial Activities NDA-Enabling Stability Testing Pre-NDA Meeting with FDA Submit New Drug Applica
Slide 17: SB206 Commercialization Plan
NOVAN.COMNOVAN.COM 17 SB206 COMMERCIALIZATION PLAN Commercialization of SB206 with Syneos Health’s Integrated Support Model, if Approved End-to-end commercial solution provider with proven track record of supporting successful commercial launches Provides immediate access to robust, existing commerc
Slide 18: SB206 Commercial Approach
NOVAN.COM SB206 COMMERCIAL APPROACH 18 • Communication • Education • Evidence Base • Early Engagement • Economic Burden • Commercial Formulary • Digital Health • Build the brand • Establish Differentiation • Efficiently Target Stakeholders • Amplify Reach Generate data and build the holistic evidenc
Slide 19: Competitive Landscape
NOVAN.COM COMPETITIVE LANDSCAPE 191. Syneos Health Consulting Primary (n=40 Pediatricians, n=39 Dermatologists, n=4 Pediatric Dermatologists) and Secondary Research (2019) Today, approximately 1.3 million new U.S. cases diagnosed annually1 Potential Therapy Characteristics Topical – SB206 In-home tr
Slide 20: SB204 Acne Vulgaris
NOVAN.COM SB204 Acne Vulgaris Late-stage asset with two completed Phase 3 studies Priority Pipeline Expansion 20
Slide 21: SB204: Advance Development for Acne Vulgaris
NOVAN.COM SB204: ADVANCE DEVELOPMENT FOR ACNE VULGARIS Potential advantages over other topical therapies for the most common form of acne 21 Multi-factorial mechanism of action, including anti-bacterial and anti-inflammatory Convenience of once daily application Excellent local tolerability and favo
Slide 22: Data from Positive Phase 3 Study
NOVAN.COM DATA FROM POSITIVE PHASE 3 STUDY 22*Analysis includes all patients who were randomized. Absolute changes in lesion count reduction are shown as LSMean NI-AC302 ITT* (n = 1327) Non-Inflammatory Lesion Reduction SB204 -14.8 Vehicle -12.1 p-value p=0.001 Inflammatory Lesion Reduction SB204 -1
Slide 23: SB204 Acne Vulgaris: Why we are planning for success
NOVAN.COM SB204 Acne Vulgaris: Why we are planning for success 23 FDA GUIDANCE: JUST ONE MORE PIVOTAL PHASE 3 TRIAL AC302 was a successful pivotal Phase 3 trial across all three co-primary endpoints Consistent results across AC301 and AC302 for two of three co-primary endpoints Positive B-SIMPLE4 re
Slide 24: Regulatory Path for SB204 in Acne
NOVAN.COM REGULATORY PATH FOR SB204 IN ACNE 24 Targeted Timeline: Two Phase 3 studies completed in 2017 One pivotal Phase 3 study to be conducted Size of trial estimated to include >1,000 patients 3 co-primary endpoints (non-inflammatory lesions, inflammatory lesions, IGA success) Prepare for Pivota
Slide 25: Acne Vulgaris Market Potential
NOVAN.COM ACNE VULGARIS MARKET POTENTIAL We believe among dermatology health-care providers there remains a significant unmet need for novel mechanisms of action with favorable tolerability profiles to improve patient outcomes in acne 25 ~50 million people with acne in the U.S.1 Topical U.S. acne ma
Slide 26: SB019 COVID-19
NOVAN.COM SB019 COVID-19 26 Phase 1 in healthy volunteers in 1H 2022
Slide 27: SB019: Advance Development for COVID-19
NOVAN.COM SB019: Advance Development for COVID-19 Intranasal administration may reduce viral burden in the nasal epithelium and lead to reduced transmission, disrupted disease progression, and alleviated symptoms 27 Nitric oxide known to have potent anti-viral properties Strong preclinical and clini
Slide 28: Regulatory Path for SB019 in COVID-19
NOVAN.COM REGULATORY PATH FOR SB019 IN COVID-19 28 Pre-clinical IND enabling studies completed1 Candidate formulation administered intranasally in animals Berdazimer sodium well-tolerated up to the maximum dose tested Drug-device combination in development for potential Phase 2/3 study(s) 1. Assumes
Slide 29: The Full Opportunity
NOVAN.COM The Full Opportunity Building a fully integrated dermatology and anti-infectives company 29
Slide 30: Robust IP Protection
NOVAN.COM ROBUST IP PROTECTION Over 35 issued US patents, over 125 issued non-US patents and over 85 pending applications throughout the world 30 NITRICIL™ Technology Patent Expiration1 Composition of Matter to 2026 Method of Manufacture to 2032 Formulation Science Formulation Composition and Manufa
Slide 31: Milestones in Next Months
NOVAN.COM MILESTONES IN NEXT 12 MONTHS 31 2H 2021 1H 2022 Final Safety Results B-SIMPLE4 for SB206 Launch Pre-Commercial Activities for SB206 Submit SB019 Pre-IND Initiate Phase 1 with SB019 SB206 Pre-NDA Meeting with FDA Submit SB206 NDA
Slide 32: Fully Integrated Team Specifically Designed to Execute Strategy
NOVAN.COM FULLY INTEGRATED TEAM SPECIFICALLY DESIGNED TO EXECUTE STRATEGY 32 Tomoko Maeda-Chubachi, MD, Ph.D., MBA Chief Medical Officer John M. Gay, CPA Chief Financial Officer Carri Geer, Ph.D. Chief Technology Officer Paula Brown Stafford, MPH Chairman and Chief Executive Officer Leveraging Exten
Slide 33: Novan PRIDE Underpins Our Efforts
NOVAN.COM NOVAN PRIDE UNDERPINS OUR EFFORTS 33
Slide 34: Why Novan, Why Now
NOVAN.COM Why Novan, Why Now A world leader in nitric oxide-based science, technology, and clinical translation in support of delivering safe and efficacious therapies 34 NITRICIL™ technology platform allows stable, tunable, and targeted delivery of therapeutic quantities of NO Robust body of data w
Slide 35: Thank You
Nitric Oxide-Based Medicine N A S D A Q : N O V N | n o v a n . c o m INVESTOR RELATIONS JTC Team 833.475.8247 novn@jtcir.com Thank You!